This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D70 (drug-induced neutropenia/agranulocytosis) | Special Copayment Reduction: V285 (severe intractable disease, 5 years) |
| B. Synonyms | Drug-induced agranulocytosis, drug-induced neutropenia, drug-induced granulocytopenia, immune drug-induced neutropenia |
| C. Adult onset | Likelihood of adult onset: very high — most patients taking causative drugs (antithyroid drugs, antipsychotics, antibiotics, etc.) are adults, and the median age is reported to be in the 50s–60s. |
| 1. History | 1922: Schultz first described agranulocytosis → 1930s–40s: reports associated with sulfonamides and aminopyrine → establishment of clozapine monitoring systems → era of pharmacogenomics. |
| 2. Causes | Clozapine, antithyroid drugs (methimazole, PTU), carbimazole, sulfonamides, ticlopidine, quinine, phenytoin, carbamazepine, antimalarials, some antibiotics. |
| 3. Genetics | HLA-B*38:02 and HLA-DQB1*05:02 (clozapine), GSTT1 deletion, and CYP polymorphisms contribute to risk. |
| 4. General epidemiology | Incidence of drug-induced agranulocytosis 1–15 per million per year; clozapine 1–2%, methimazole 0.1–0.5%; increased risk in women and the elderly. |
| 5. Pathophysiology | Immune-mediated (hapten formation → anti-neutrophil antibodies or T-cell-mediated granulocyte destruction), direct toxicity (anticancer drugs), suppression of bone marrow progenitor cells. |
| 6. Symptoms | Fever, chills, sore throat (the most common initial symptom), oral ulcers, bacterial and fungal infections (pneumonia, sepsis, perianal infection). |
| 7. Signs | Absolute neutrophil count (ANC) <1,000/μL (agranulocytosis: ANC <100–500/μL); fever; pharyngeal exudate; oral mucositis; selective neutropenia on CBC. |
| 8. Screening | Clozapine: mandatory ANC monitoring before administration, weekly for 18 weeks, and every other week thereafter; methimazole: confirm baseline CBC before administration and immediate CBC if fever or sore throat occurs. |
| 9. Diagnosis | CBC + differential white blood cell count; peripheral blood smear; bone marrow examination (confirm maturation arrest of precursor cells); anti-neutrophil antibodies; confirmation of history of causative drug use. |
| 10. Treatment | Immediate discontinuation of the causative drug; broad-spectrum antibiotics and antifungals for fever; G-CSF (filgrastim 5 μg/kg/day); reverse isolation; prophylactic antibiotics and antifungals. |
| 11. Prognosis | About 7–14 days until ANC recovery after drug discontinuation + G-CSF; mortality from sepsis and pneumonia before recovery 5–10%; good prognosis with early detection. |
| 12. Prevention | Mandatory CBC monitoring when giving high-risk drugs; education to have a CBC done immediately if fever or sore throat occurs; preferential selection of alternative drugs. |
| 13. References | Andres E et al. QJM 2004 and 9 other papers |
The term agranulocytosis was first used in 1922 by Werner Schultz, who observed a marked decrease in granulocytes in patients with severe throat infection and described it as an independent clinical entity. At first the cause of agranulocytosis was unclear, but in 1931 Kracke first reported an association with taking aminopyrine (aminophenazone), and drugs began to attract attention as a cause. Cases of aminopyrine-induced agranulocytosis then surged, and thousands of patients died in the United States and Europe in the 1930s, recorded as one of the most tragic events in the history of drug-induced hematologic toxicity. Aminopyrine was eventually withdrawn from the market in most countries after the 1940s.
In the 1940s–50s, associations of agranulocytosis with various drugs such as sulfonamide antibiotics and phenylbutazone were reported. Agranulocytosis due to antithyroid drugs (propylthiouracil, methimazole) has been known since the 1940s and remains an important clinical problem today. In the 1960s–70s the antipsychotic clozapine was introduced, but it was withdrawn from the market after 13 people died in Finland in 1975 from the serious adverse effect of agranulocytosis. However, because the therapeutic efficacy of clozapine is markedly superior to other antipsychotics, it was re-approved in the United States in 1990 together with a mandatory CBC monitoring program. This clozapine monitoring system is presented as a model for surveillance of drug-induced agranulocytosis.
In mechanistic research, an immune-mediated mechanism (formation of anti-neutrophil antibodies by drug-protein complexes) was established in the 1970s–80s as the main pathological mechanism. With the development of pharmacogenomics from the 1990s, associations between HLA genotypes and specific drug-induced agranulocytosis began to be identified. With the approval of G-CSF (granulocyte colony-stimulating factor) in 1991, it began to be used to promote recovery from agranulocytosis, which contributed to reduced mortality.
The main drug groups causing drug-induced neutropenia/agranulocytosis are as follows.
Clozapine is one of the best-known causes of drug-induced agranulocytosis; agranulocytosis occurs in about 1–2% of users, mostly within 4–18 weeks after starting. The key to the immune-mediated mechanism is that the reactive nitrenium ion metabolite of clozapine covalently binds to neutrophil membrane proteins to form a hapten.
The incidence of agranulocytosis with methimazole and propylthiouracil (PTU) is about 0.1–0.5%. It occurs mainly within the first 3 months after starting treatment. Methimazole is known to carry a slightly higher risk of agranulocytosis than PTU, but PTU has a higher risk of hepatotoxicity, so methimazole is preferred except in the first trimester of pregnancy.
Sulfonamides (trimethoprim-sulfamethoxazole), penicillins (especially semisynthetic penicillins: methicillin, oxacillin), chloramphenicol, vancomycin, linezolid (with long-term use), and antimalarials (quinine, chloroquine) are reported as causative drugs.
Carbamazepine, phenytoin, and valproic acid are rarely associated. The antiplatelet drug ticlopidine is known to carry a 0.8% risk of agranulocytosis, and its use is now restricted. In addition, allopurinol, D-penicillamine, gold compounds, antirheumatic drugs (sulfasalazine), some antihypertensives, and H2 receptor antagonists (cimetidine) are reported.
The HLA association with clozapine-induced agranulocytosis is the best studied. Studies indicate that HLA alleles such as HLA-B*38:02, HLA-DQB1*05:02, and HLA-DRB1*08:01 are associated with the risk of clozapine agranulocytosis, but because predictive sensitivity and specificity are insufficient, they are not currently used as routine tests in clinical practice. A recent genome-wide association study (GWAS) reported that a particular genotype in the HLAD region is associated with clozapine agranulocytosis. In terms of drug metabolism, CYP1A2 and CYP3A4 genotypes affect the blood concentrations of clozapine and its metabolites and may contribute to toxicity risk. GSTT1 deletion is associated with reduced capacity to detoxify the clozapine nitrenium ion. Case reports associate methimazole agranulocytosis with HLA-B*27:05, and association studies with particular HLA alleles in Asian populations are ongoing.
The overall incidence of drug-induced agranulocytosis is estimated at about 1–15 per million per year in the West (with wide variation among studies). Incidence by specific drug: clozapine about 1–2%, methimazole/PTU about 0.1–0.5%, sulfonamides about 0.01–0.06%, ticlopidine about 0.8% (use now greatly reduced). By sex, it occurs about 2–3 times more often in women. By age, risk increases in the elderly aged 60 and older. The period of drug exposure is mostly within the first 3 months, but for some drugs (clozapine) there is a risk period of 1–18 weeks. In Korea, agranulocytosis related to antithyroid drugs is recognized as an important adverse effect during treatment of hyperthyroidism, and given the high prevalence of hyperthyroidism, related cases are not few.
The main mechanisms of drug-induced neutropenia are broadly divided into immune-mediated and direct toxicity.
When a drug or reactive metabolite binds to neutrophil membrane proteins to form a hapten or alters protein structure (altered peptide), the immune system recognizing it as a self-antigen is activated. Main pathways: ① Anti-neutrophil antibodies: IgG or IgM antibodies bind to the neutrophil surface and induce complement activation or macrophage-mediated destruction via Fc receptors. ② T-cell-mediated mechanism: CD8+ CTLs presented with drug-protein complexes directly destroy neutrophils. ③ Suppression of bone marrow progenitor cells: in some cases, antibodies or cytotoxic T cells attack progenitor cells in the bone marrow (promyelocytes, myelocytes) and block neutrophil production itself. This mechanism appears as maturation arrest on bone marrow examination.
Anticancer drugs (alkylating agents, antimetabolites, vinca alkaloids, etc.) suppress proliferation of bone marrow granulocytic precursor cells through dose-dependent direct toxicity. The nitrenium ion of clozapine can also directly cause oxidative damage to the neutrophil cell membrane and induce apoptosis. Oxidative stress → ROS generation → loss of mitochondrial membrane potential → cell death.
The initial symptoms of drug-induced agranulocytosis are nonspecific, so a CBC should be performed immediately when fever and infection symptoms occur in patients taking high-risk drugs. Fever (body temperature 38.3°C or higher) is the most common and important initial symptom. Chills and generalized weakness accompany. Sore throat and oral mucosal ulcers are characteristic and are a direct result of loss of the neutrophils responsible for oral mucosal defense. With progression, bacterial infections develop, such as upper respiratory tract infection (tonsillitis, epiglottitis), pneumonia, urinary tract infection, and perianal abscess. In severe neutropenia (ANC <100–200/μL), rapid deterioration to sepsis and septic shock can occur. Invasive fungal infection (Aspergillus pneumonia, Candida esophagitis) carries a greatly increased risk when neutropenia lasts 7–10 days or longer.
The key finding on CBC is a decreased absolute neutrophil count (ANC). ANC = total white blood cell count × (neutrophil % + band neutrophil %) / 100. Neutropenia: ANC <1,500/μL; severe neutropenia: ANC <500/μL; agranulocytosis: ANC <100–200/μL (definitions differ somewhat). Importantly, the red cell and platelet lines are mostly normal, so selective neutropenia is seen. On the peripheral blood smear, a decreased neutrophil count is confirmed, and toxic granulation is an indirect sign of active infection. On bone marrow examination, maturation arrest of the granulocytic lineage — maturation halted at the myelocyte or promyelocyte stage — is the characteristic finding of immune-mediated agranulocytosis. On physical examination, fever, pharyngeal redness and exudate, oral mucosal ulcers, tonsillar enlargement, and perianal redness and tenderness are found. Hypotension, tachycardia, and respiratory symptoms may accompany depending on the severity of infection.
Systematic ANC monitoring of high-risk drugs is key to early detection of drug-induced agranulocytosis. Clozapine: under the US FDA-approved REMS (Risk Evaluation and Mitigation Strategy) program, confirm baseline ANC before starting treatment (ANC must be ≥1,500/μL to start), then measure ANC weekly for the first 6 months, every 2 weeks for the next 6 months, and monthly thereafter. Similar monitoring guidelines apply in Europe and Korea. Methimazole/PTU: perform a baseline CBC before administration and educate patients in advance to have a CBC done immediately if infection symptoms such as fever or sore throat occur. Some experts recommend CBC every other month for the first 3 months after starting treatment. In patients on sulfasalazine, ticlopidine, or long-term penicillins, perform a CBC immediately if fever occurs during the administration period.
If fever or infection symptoms occur in a patient taking a high-risk drug, perform a CBC + differential white blood cell count immediately. After confirming ANC <1,500/μL, assess the temporal association with the causative drug. On the peripheral blood smear, confirm decreased neutrophil count, toxic granulation, and cell abnormalities due to neutrophil cytotoxic antibodies. Bone marrow aspiration and biopsy are performed to analyze the cause of agranulocytosis and for differential diagnosis (excluding aplastic anemia, MDS, and leukemic infiltration). Maturation arrest is characteristic of immune-mediated agranulocytosis, and depletion of granulocytic precursor cells suggests direct toxicity. Anti-neutrophil antibody testing (indirect immunofluorescence, GIFT) can be used to confirm an immune-mediated mechanism, but sensitivity and specificity are not perfect. To identify the cause of infection, two sets of blood cultures (aerobic and anaerobic), urine culture, and chest X-ray or CT if necessary are performed.
The most important initial step in drug-induced agranulocytosis is immediate discontinuation of the causative drug. Thereafter, treating infection and promoting neutrophil recovery are the key to treatment.
If fever (38.3°C or higher once, or 38.0°C for 1 hour or longer) occurs at ANC <500/μL, administer broad-spectrum antibiotics intravenously immediately. Start antibiotics within 30–60 minutes after drawing blood cultures. Empirical antibiotic selection: antipseudomonal beta-lactam (piperacillin-tazobactam, cefepime, meropenem) ± vancomycin (for catheter-related infection, suspected pneumonia, or skin and soft tissue infection). Prevention of fungal infection: fluconazole (Candida prophylaxis) or azole/echinocandin (Aspergillus prophylaxis in severe neutropenia lasting 7 days or more). Reverse (protective) isolation is used to prevent additional infection.
Starting granulocyte colony-stimulating factor (G-CSF, filgrastim or lenograstim) 5 μg/kg/day by subcutaneous injection shortens the period of ANC recovery and reduces the risk of severe infection. The evidence for G-CSF use in drug-induced agranulocytosis is mainly at the level of observational studies, but a trend toward reduced mortality was found in meta-analyses, so its use is recommended in severe cases. Discontinue G-CSF when ANC recovers to 1,000/μL or higher.
ANC recovery generally takes 7–14 days after drug discontinuation, and the recovery period is shortened with G-CSF. When detected early (at the beginning of ANC decline, before infection occurs), prognosis is good and most patients recover fully. Once sepsis has occurred, mortality is about 5–10% (varying between reports) and increases markedly if it progresses to septic shock. Old age, severe underlying disease, a very low ANC (complete agranulocytosis), diagnostic delay, and concomitant invasive fungal infection are poor prognostic factors. Re-administration of the same drug after recovery is contraindicated, and an alternative drug must be used. For clozapine, some specialist centers consider reuse under strict monitoring in special cases (treatment-resistant psychosis).
Systematic monitoring of high-risk drugs is the key to prevention. For clozapine, strictly adhere to the prescribed ANC monitoring program, and discontinue the drug immediately if ANC falls below the threshold. Educate patients taking methimazole or PTU to visit a medical institution immediately and have a CBC done if fever or sore throat occurs. For treating hyperthyroidism, considering radioactive iodine therapy or surgery first instead of antithyroid drugs is the way to eliminate the risk of agranulocytosis at its source. Preferentially choose lower-risk alternative drugs, as in selecting clopidogrel instead of ticlopidine. Perform regular CBC monitoring with long-term penicillin administration.